Mar 03, 2009 - 2:07 pm
I won't pretend to completely understand this, but I came across this new research on UPSC on the Cancer Society Institute and wanted to share it, especially the hormone therapy for California_Artist:
Tumor Suppressor Genes. National cancer Institute is also supporting efforts to isolate a novel tumor suppressor gene that is involved in the development of uterine papillary serous carcinoma (UPSC), the most aggressive type of endometrial cancer. The research has identified a specific mutation in approximately 65 percent of UPSCs.
Hormonal Therapies. A Phase 2 trial is comparing an estrogen blocker and receptor modulator in patients with recurrent, metastatic endometrial cancer. An NSABP study found that progesterone exerts molecular effects in cancerous endometrial cells including cyclin p21 and p27 induction, decreasing proliferation and inhibiting invasion. In progesterone receptor B expressing cells, it induces a secretory phenotype. Array analysis also showed inhibition of a number of cellular adhesion molecules. Another study showed that in poorly differentiated endometrial cancer cells, the introduction of progesterone receptors A and B allowed progestin to re-exert regulatory effects on proliferation.
Alternate-substituted alkyl PCDFs are a new mechanism-based class of antiestrogens that block estrogen-induced mammary and endometrial cell/tumor growth via crosstalk between the ER and Ah receptor signaling pathways. These compounds have been shown to be relatively nontoxic, inhibit ER-positive and ER-negative mammary tumor growth, and synergize with tamoxifen to inhibit breast cancer growth and block tamoxifen-induced estrogenic activity in the uterus.